Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$846M |
| 2 |
JD.com
JD
|
+$782M |
| 3 |
Dollar General
DG
|
+$647M |
| 4 |
Monster Beverage
MNST
|
+$324M |
| 5 |
NXP Semiconductors
NXPI
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$668M |
| 2 |
Mondelez International
MDLZ
|
+$528M |
| 3 |
Alibaba
BABA
|
+$457M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$409M |
| 5 |
CELG
Celgene Corp
CELG
|
+$403M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.97% |
| 2 | Consumer Discretionary | 16.01% |
| 3 | Technology | 12.95% |
| 4 | Communication Services | 12.43% |
| 5 | Financials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN.PRA
526
DELISTED
Allergan plc
AGN.PRA
| $7.84M | 0.01% |
+7,500
| New | +$7.85M |
|
|
PRTK
527
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $7.77M | 0.01% |
+301,514
| New | +$8.56M |
|
|
NVRO
528
DELISTED
NEVRO CORP.
NVRO
| $7.35M | 0.01% |
136,760
-8,186
| -6% | -$417K |
|
529
Rocket Pharmaceuticals
RCKT
$343M
| $7.22M | 0.01% |
368,614
+118,384
| +47% | +$2.62M |
|
|
TEP
530
DELISTED
Tallgrass Energy Partners, LP
TEP
| $6.58M | 0.01% |
136,837
+4,355
| +3% | +$216K |
|
|
ADAP
531
DELISTED
Adaptimmune Therapeutics
ADAP
| $6.42M | 0.01% |
+350,000
| New | +$6.01M |
|
|
EPZM
532
DELISTED
Epizyme, Inc
EPZM
| $6.05M | 0.01% |
252,117
+1,979
| +0.8% | +$38.1K |
|
|
BLCM
533
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $5.87M | 0.01% |
27,573
-38,070
| -58% | -$9.33M |
|
|
ESPR
534
DELISTED
Esperion Therapeutics
ESPR
| $5.78M | 0.01% |
70,720
+673
| +1% | +$65.9K |
|
535
SCYNEXIS
SCYX
$37.4M
| $5.24M | ﹤0.01% |
+7,456
| New | +$5.35M |
|
|
TRNX
536
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $5.19M | ﹤0.01% |
207,769
+2,091
| +1% | +$54.4K |
|
|
ZSPH
537
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $5.16M | ﹤0.01% |
98,479
+983
| +1% | +$48.4K |
|
538
Webster Financial
WBS
$12.3B
| $5.08M | ﹤0.01% |
128,423
-26,226
| -17% | -$989K |
|
|
CNCE
539
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $4.98M | ﹤0.01% |
334,686
-145,536
| -30% | -$2.22M |
|
|
BPL
540
DELISTED
Buckeye Partners, L.P.
BPL
| $4.81M | ﹤0.01% |
65,118
+26,371
| +68% | +$2.07M |
|
|
WPZ
541
DELISTED
Williams Partners L.P.
WPZ
| $4.75M | ﹤0.01% |
97,968
+20,224
| +26% | +$1.05M |
|
542
Asbury Automotive
ABG
$4.62B
| $4.7M | ﹤0.01% |
51,911
-8,586
| -14% | -$745K |
|
543
Power Integrations
POWI
$3.15B
| $4.61M | ﹤0.01% |
204,266
-1,140,452
| -85% | -$28.5M |
|
544
Valley National Bancorp
VLY
$7.9B
| $4.6M | ﹤0.01% |
446,083
-61,576
| -12% | -$600K |
|
545
ExxonMobil
XOM
$650B
| $4.55M | ﹤0.01% |
54,697
-1,134
| -2% | -$97.5K |
|
|
RGLS
546
DELISTED
Regulus Therapeutics
RGLS
| $4.46M | ﹤0.01% |
3,395
+34
| +1% | +$54.9K |
|
|
EEP
547
DELISTED
Enbridge Energy Partners
EEP
| $4.34M | ﹤0.01% |
130,317
+49,609
| +61% | +$1.83M |
|
|
IMDZ
548
DELISTED
Immune Design Corp.
IMDZ
| $4.16M | ﹤0.01% |
+201,459
| New | +$4.76M |
|
549
Sunoco
SUN
$14.4B
| $4.15M | ﹤0.01% |
91,580
+4,514
| +5% | +$217K |
|
|
GNMX
550
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $4.15M | ﹤0.01% |
676,870
-291,922
| -30% | -$2.26M |
|
Similar funds
Jennison Associates's Q2 2015 Portfolio in Review
As of Q2 2015, Jennison Associates held 801 positions worth $109B, down 0.05% from $109B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Jennison Associates's Q2 2015 filing shows 92 new, 315 increased, 305 reduced and 72 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M. The largest sale was Union Pacific, an estimated $668M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Technology.
- Jennison Associates's largest Q2 2015 buy was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M.
- Jennison Associates added most to JD.com in Q2 2015, an estimated $782M increase.
- Jennison Associates's biggest Q2 2015 reduction was Union Pacific, cutting an estimated $668M.
- Jennison Associates fully exited Perrigo in Q2 2015, selling an estimated $204M.
- Jennison Associates's ten largest holdings make up 21% of its $109B portfolio in Q2 2015.
- Jennison Associates opened 92 new positions and closed 72 in Q2 2015.
- Jennison Associates's portfolio value fell 0.05% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q2 2015, filed 3 Aug 2015.